Caribou Biosciences (CRBU) Net Cash Flow Growth (1y) (2021 - 2026)
Caribou Biosciences (CRBU) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-14,223.53% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Caribou Biosciences |
156.73 Mn |
39.11 Mn |
- |
-102.43% |
| Date | Value |
|---|
| Mar 31, 2026 |
-102.43% |
| Dec 31, 2025 |
107.71% |
| Sep 30, 2025 |
-138.42% |
| Jun 30, 2025 |
63.45% |
| Mar 31, 2025 |
844.84% |
| Dec 31, 2024 |
70.36% |
| Sep 30, 2024 |
-115.57% |
| Jun 30, 2024 |
-185.75% |
| Mar 31, 2024 |
68.50% |
| Dec 31, 2023 |
-122.75% |
| Sep 30, 2023 |
225.96% |
| Jun 30, 2023 |
137.90% |
| Mar 31, 2023 |
93.97% |
| Dec 31, 2022 |
87.82% |
| Sep 30, 2022 |
-109.83% |
| Jun 30, 2022 |
-116.97% |
| Mar 31, 2022 |
-171.39% |
| Dec 31, 2021 |
-2,167.74% |
| Sep 30, 2021 |
3,662.69% |
